Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Thomas Gaines

Interventional Cardiology Metairie, LA Medical Doctor

NPI 1679731574 CMS profile 753109

3530 Houma Blvd Ste 300, Metairie, LA 70006

Open in the dashboard

General payments

$3,295

83 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Thomas Gaines of Metairie, LA is reported in the CMS Open Payments database as having received $3,295 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $121 1
2023 General $82 3
2022 General $18 1
2021 General $41 1
2020 General $1,993 42
2019 General $1,039 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gaines
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Thomas Gaines were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Thomas Gaines Interventional Cardiology median Middle half National median
2019 $1,039 $1,097 $329–$3,048 $163
2020 $1,993 $473 $161–$1,480 $114
2021 $41 $677 $233–$1,827 $132
2022 $18 $978 $333–$2,724 $149
2023 $82 $1,136 $382–$2,986 $160
2024 $121 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Abbott Laboratories $1,255 15 payments
  2. Abiomed $392 3 payments
  3. Amgen Inc. $333 11 payments
  4. Cardiovascular Systems Inc. $274 6 payments
  5. Edwards Lifesciences Corporation $170 2 payments
  6. Janssen Pharmaceuticals, Inc $124 8 payments
  7. Chiesi USA, Inc. $110 1 payment
  8. Pfizer Inc. $104 5 payments
  9. Regeneron Healthcare Solutions, Inc. $93 4 payments
  10. Novartis Pharmaceuticals Corporation $91 6 payments
  11. Other $348 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,143 74 payments
  2. Travel and Lodging $1,152 9 payments
Products named General payments · program years 2019–2024
  1. Assurity Pacemaker Cardiac Rhythm Management $1,027 10 payments
  2. Impella $392 3 payments
  3. Repatha $333 11 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $170 2 payments
  5. Assurity Pacemaker Cardiac Arrhythmias and Heart Failure $169 3 payments
  6. Peripheral Orbital Atherectomy System $165 3 payments
  7. KENGREAL $110 1 payment
  8. XARELTO $106 7 payments
  9. ELIQUIS $104 5 payments
  10. PRALUENT $93 4 payments
  11. Other $827 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,500

Median for Interventional Cardiology: 2,236

Drug cost

$112,241

Median for Interventional Cardiology: $380,412

Branded share of claims

15.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 80 $67,556
Repatha Sureclick Evolocumab Brand 12 $15,002
Entresto Sacubitril/Valsartan Brand 17 $11,012
Brilinta Ticagrelor Brand 11 $6,580
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $1,532
Metoprolol Succinate Generic 151 $1,062
Valsartan Generic 61 $856
Cilostazol Generic 53 $832
Bumetanide Generic 46 $652
Flecainide Acetate Generic 20 $641

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record